Italy Fines Apple €98.6 Million Over App Store Dominance 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
CAMBRIDGE, Mass., Oct. 14, 2016 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the European Society of Gene & Cell Therapy Congress (ESGCT) in Florence, Italy from October 18-21, 2016. Abstracts will be available online at esgct.eu on October 17, 2016.
“The data being presented at ESGCT show Intellia’s continued progress with its CRISPR/Cas9 platform,” said John Leonard, M.D., chief medical officer, Intellia Therapeutics. “These findings are important as we learn more about CRISPR/Cas9 and move toward clinical studies in patients.”
The following posters have been scheduled for presentation:
| Number | Poster Title | Presenter | Time |
| #283 | Efficient assessment of CRISPR/Cas9 off-target activity using a background double-strand break model | Reynald Lescarbeau, Ph.D. Computational Scientist, Bioinformatics | October 19, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #280 | Robust in vivo gene editing in mouse hepatocytes with systemic lipid nanoparticle delivery of CRISPR/Cas9 components | David Morrissey, Ph.D. Chief Technology Officer | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #320 | DNA repair events after cleavage by CRISPR/Cas9 are not random | Walter Strapps, Ph.D. Senior Director, Biology | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #310 | Translating CRISPR/Cas9 genome editing into therapeutics | Tom Barnes, Ph.D. Chief Scientific Officer | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 224-804-4462 [email protected] Investor Contacts: John Graziano Trout Group +1 646-378-2942 [email protected] Chad Rubin Trout Group +1 646-378-2947 [email protected]
